COMMUNIQUÉS West-GlobeNewswire

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
06/05/2025
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the [...]
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025
06/05/2025
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025
06/05/2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Cellectis to Report First Quarter Financial Results on May 12, 2025
06/05/2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Cellectis publiera ses résultats financiers du premier trimestre le 12 mai 2025
06/05/2025
NEW YORK, 06 mai 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
06/05/2025
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), [...]
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
06/05/2025
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright [...]
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
06/05/2025
Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25 New strategic collaboration with Lilly ExploR&D expands therapeutic approach to [...]
MacroGenics Announces Date of First Quarter 2025 Financial Results
06/05/2025
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics [...]
Sienna Reports First Quarter 2025 Financial Results and Continues Platform Expansion
06/05/2025
MARKHAM, Ontario, May 06, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three months ended March 31, 2025. Q1 2025 Highlights [...]
Jin Medical International Ltd. – Nasdaq Minimum Bid Price Non-Compliance
06/05/2025
Changzhou City, China, May 06, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ: ZJYL) (the “Company”) today announced that on May 2, 2025, it received a deficiency letter (the “Notice”) from the Nasdaq [...]
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
06/05/2025
WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided [...]
SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025
06/05/2025
SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the [...]
Supernus Announces First Quarter 2025 Financial Results
06/05/2025
First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI ® increased 16% to $30.7 million, compared to the same period in [...]
Pennant Reports First Quarter 2025 Results
06/05/2025
Conference Call and Webcast scheduled for tomorrow, May 7, 2025 at 10:00 am MT EAGLE, Idaho, May 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated [...]
LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance
06/05/2025
Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70% Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period Telehealth adjusted EBITDA increased to $5.3 [...]
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
06/05/2025
Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds 1 of $16 million, revenue increased 5% year-over-year. First quarter 2025 Prenatal revenue grew 11% year-over-year [...]
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
06/05/2025
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude’s once daily, [...]
89bio to Participate in Upcoming Investor Conferences
06/05/2025
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]

Pages